Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Angiotensin Receptor Blockers (ARBs) Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Valsartan
      • 1.3.3 Telmisartan
      • 1.3.4 Losartan
      • 1.3.5 Irbesartan
      • 1.3.6 Azilsartan
      • 1.3.7 Olmesartan
    • 1.4 Market Segment by Application
      • 1.4.1 Global Angiotensin Receptor Blockers (ARBs) Market Share by Application (2019-2025)
      • 1.4.2 Hypertension
      • 1.4.3 Cardiovascular Diseases
      • 1.4.4 Kidney Diseases
      • 1.4.5 Other
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Angiotensin Receptor Blockers (ARBs) Market Size
      • 2.1.1 Global Angiotensin Receptor Blockers (ARBs) Revenue 2014-2025
      • 2.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales 2014-2025
    • 2.2 Angiotensin Receptor Blockers (ARBs) Growth Rate by Regions
      • 2.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Regions 2014-2019
      • 2.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers
      • 3.1.1 Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers 2014-2019
      • 3.1.2 Angiotensin Receptor Blockers (ARBs) Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Angiotensin Receptor Blockers (ARBs) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Angiotensin Receptor Blockers (ARBs) Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Angiotensin Receptor Blockers (ARBs) Market Concentration Ratio (CR5 and HHI)
    • 3.3 Angiotensin Receptor Blockers (ARBs) Price by Manufacturers
    • 3.4 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Angiotensin Receptor Blockers (ARBs) Market
    • 3.6 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Valsartan Sales and Revenue (2014-2019)
      • 4.1.2 Telmisartan Sales and Revenue (2014-2019)
      • 4.1.3 Losartan Sales and Revenue (2014-2019)
      • 4.1.4 Irbesartan Sales and Revenue (2014-2019)
      • 4.1.5 Azilsartan Sales and Revenue (2014-2019)
      • 4.1.6 Olmesartan Sales and Revenue (2014-2019)
    • 4.2 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type
    • 4.3 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type
    • 4.4 Angiotensin Receptor Blockers (ARBs) Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Application

    6 United States

    • 6.1 United States Angiotensin Receptor Blockers (ARBs) Breakdown Data by Company
    • 6.2 United States Angiotensin Receptor Blockers (ARBs) Breakdown Data by Type
    • 6.3 United States Angiotensin Receptor Blockers (ARBs) Breakdown Data by Application

    7 European Union

    • 7.1 European Union Angiotensin Receptor Blockers (ARBs) Breakdown Data by Company
    • 7.2 European Union Angiotensin Receptor Blockers (ARBs) Breakdown Data by Type
    • 7.3 European Union Angiotensin Receptor Blockers (ARBs) Breakdown Data by Application

    8 China

    • 8.1 China Angiotensin Receptor Blockers (ARBs) Breakdown Data by Company
    • 8.2 China Angiotensin Receptor Blockers (ARBs) Breakdown Data by Type
    • 8.3 China Angiotensin Receptor Blockers (ARBs) Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Angiotensin Receptor Blockers (ARBs) Breakdown Data by Company
    • 9.2 Rest of World Angiotensin Receptor Blockers (ARBs) Breakdown Data by Type
    • 9.3 Rest of World Angiotensin Receptor Blockers (ARBs) Breakdown Data by Application
    • 9.4 Rest of World Angiotensin Receptor Blockers (ARBs) Breakdown Data by Countries
      • 9.4.1 Rest of World Angiotensin Receptor Blockers (ARBs) Sales by Countries
      • 9.4.2 Rest of World Angiotensin Receptor Blockers (ARBs) Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Pfizer
      • 10.1.1 Pfizer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.1.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.1.5 Pfizer Recent Development
    • 10.2 Novartis
      • 10.2.1 Novartis Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.2.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.2.5 Novartis Recent Development
    • 10.3 Merck
      • 10.3.1 Merck Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.3.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.3.5 Merck Recent Development
    • 10.4 Astra Zeneca
      • 10.4.1 Astra Zeneca Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.4.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.4.5 Astra Zeneca Recent Development
    • 10.5 Jhonson and Johnson
      • 10.5.1 Jhonson and Johnson Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.5.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.5.5 Jhonson and Johnson Recent Development
    • 10.6 Eli Lilly
      • 10.6.1 Eli Lilly Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.6.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.6.5 Eli Lilly Recent Development
    • 10.7 Sanofi
      • 10.7.1 Sanofi Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.7.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.7.5 Sanofi Recent Development
    • 10.8 Bristol-Myers Squibb
      • 10.8.1 Bristol-Myers Squibb Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.8.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.8.5 Bristol-Myers Squibb Recent Development
    • 10.9 Bayer
      • 10.9.1 Bayer Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.9.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.9.5 Bayer Recent Development
    • 10.10 GSK
      • 10.10.1 GSK Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Angiotensin Receptor Blockers (ARBs)
      • 10.10.4 Angiotensin Receptor Blockers (ARBs) Product Introduction
      • 10.10.5 GSK Recent Development
    • 10.11 Teva Pharmaceutical

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Angiotensin Receptor Blockers (ARBs) Sales Channels
      • 11.2.2 Angiotensin Receptor Blockers (ARBs) Distributors
    • 11.3 Angiotensin Receptor Blockers (ARBs) Customers

    12 Market Forecast

    • 12.1 Global Angiotensin Receptor Blockers (ARBs) Sales and Revenue Forecast 2019-2025
    • 12.2 Global Angiotensin Receptor Blockers (ARBs) Sales Forecast by Type
    • 12.3 Global Angiotensin Receptor Blockers (ARBs) Sales Forecast by Application
    • 12.4 Angiotensin Receptor Blockers (ARBs) Forecast by Regions
      • 12.4.1 Global Angiotensin Receptor Blockers (ARBs) Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
      In 2019, the market size of Angiotensin Receptor Blockers (ARBs) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Angiotensin Receptor Blockers (ARBs).

      This report studies the global market size of Angiotensin Receptor Blockers (ARBs), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Angiotensin Receptor Blockers (ARBs) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Pfizer
      Novartis
      Merck
      Astra Zeneca
      Jhonson and Johnson
      Eli Lilly
      Sanofi
      Bristol-Myers Squibb
      Bayer
      GSK
      Teva Pharmaceutical

      Market Segment by Product Type
      Valsartan
      Telmisartan
      Losartan
      Irbesartan
      Azilsartan
      Olmesartan

      Market Segment by Application
      Hypertension
      Cardiovascular Diseases
      Kidney Diseases
      Other

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Angiotensin Receptor Blockers (ARBs) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Angiotensin Receptor Blockers (ARBs) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Angiotensin Receptor Blockers (ARBs) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now